30th September 2020
On 11th September 2020, Professors Hemant Kocher and Nick Lemoine hosted the eighth London Pancreas Workshop (LPW) – a forum for state-of-the-art clinical and basic research in pancreatic cancer. In a first for the biennial event, this year’s LPW took place online with pre-recorded speaker presentations and live, interactive Q&A sessions.
Read more24th September 2020
A treatment combination involving the addition of a form of vitamin A to the current standard treatment regimen for pancreatic cancer is safe for patients, according to an early phase clinical trial led by Professor Hemant Kocher from Barts Cancer Institute, Queen Mary University of London.
Read more28th April 2020
Research has revealed that the signature of metal ions present in urine samples is an accurate indicator of pancreatic ductal adenocarcinoma, one of the deadliest types of cancer.
Read more10th March 2020
The tumour microenvironment: Key to controlling cancer cell growth Research led by Barts Cancer Institute (BCI), Queen Mary University of London, reveals novel insights into the role of the tumour […]
Read more12th February 2020
Researchers at Barts Cancer Institute, Queen Mary University of London, have identified a peptide, or protein fragment, taken from the foot-and-mouth-disease virus that targets another protein, called avβ6 (alpha-v-beta-6). This protein is found at high levels on the surface of the majority of pancreatic cancer cells.
Read more26th November 2019
Researchers from Barts Cancer Institute and Zhengzhou University have developed a personalised vaccine system that could ultimately delay the onset of pancreatic cancer. The study reports the team’s work with a pre-clinical model using mice, and provides strong proof-of-concept for the creation of a vaccine for cancer prevention in individuals at high risk of developing this disease.
Read more